The global natural killer cell therapies market is expected to grow at a CAGR of 16.5% during the forecast period, from 2021 to 2030. The growth of this market can be attributed to the increasing prevalence of cancer and gastrointestinal diseases, which are major indications for NK cell therapies. The increasing number of clinical trials for NK cell therapies is also driving the growth of this market.
The global natural killer cell therapies market by type is segmented into NK Cell Therapies and NK Cell Directed Antibodies. The former includes autologous or allogeneic cells that are genetically modified with chimeric antigen receptors (CARs) or other gene-based immunotherapy approaches such as TCRs, while the latter includes monoclonal antibodies directed against specific surface markers on natural killer cells such as CD16a/CD56a/CD16b/CD56b and CD94/NKG2A receptors on these cells.
Cancer accounted for over 50% share in terms of application in 2018 owing to its high prevalence rate globally and high unmet medical need associated with it. Gastrointestinal diseases accounted for over 30% share in terms of application in 2018 owing to their high incidence rates globally and low unmet medical need associated with them among patients suffering from these conditions.
- The global population is aging and the elderly are more susceptible to cancer, which is a major driver of demand for NK cell therapies.
- The incidence of cancer has been increasing in recent years, which will also drive demand for NK cell therapies.
- Cancer treatments are becoming more personalized and targeted, which will increase the need for NK cells to be used as a complementary therapy alongside other treatments such as chemotherapy or radiation therapy.
- There is an increased focus on immunotherapy treatments in general, which will lead to increased interest in NK cell therapies.
- There are many different types of cancers that can be treated with NK cells.
Industry Growth Insights published a new data on “Natural Killer Cell Therapies Market”. The research report is titled “Natural Killer Cell Therapies Market research by Types (NK Cell Therapies, NK Cell Directed Antibodies), By Applications (Cancer, Gastrointestinal Diseases, Others), By Players/Companies Nektar Therapeutics, Innate, Affimed, Chipscreen Biosciences, Fate Therapeutics, Glycostem, Dragonfly Therapeutics, Kiadis Pharma, NantWorks, Nkarta Therapeutics, Fortress Biotech”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Natural Killer Cell Therapies Market Research Report
By Type
NK Cell Therapies, NK Cell Directed Antibodies
By Application
Cancer, Gastrointestinal Diseases, Others
By Companies
Nektar Therapeutics, Innate, Affimed, Chipscreen Biosciences, Fate Therapeutics, Glycostem, Dragonfly Therapeutics, Kiadis Pharma, NantWorks, Nkarta Therapeutics, Fortress Biotech
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
243
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
Global Natural Killer Cell Therapies Market Report Segments:
The global Natural Killer Cell Therapies market is segmented on the basis of:
Types
NK Cell Therapies, NK Cell Directed Antibodies
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Cancer, Gastrointestinal Diseases, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Nektar Therapeutics
- Innate
- Affimed
- Chipscreen Biosciences
- Fate Therapeutics
- Glycostem
- Dragonfly Therapeutics
- Kiadis Pharma
- NantWorks
- Nkarta Therapeutics
- Fortress Biotech
Highlights of The Natural Killer Cell Therapies Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- NK Cell Therapies
- NK Cell Directed Antibodies
- By Application:
- Cancer
- Gastrointestinal Diseases
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Natural Killer Cell Therapies Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Natural Killer Cell Therapies (NKCTs) are a type of cancer treatment that use natural substances to kill cancer cells. NKCTs work by attacking and killing cancer cells without harming normal tissue.
Some of the major players in the natural killer cell therapies market are Nektar Therapeutics, Innate, Affimed, Chipscreen Biosciences, Fate Therapeutics, Glycostem, Dragonfly Therapeutics, Kiadis Pharma, NantWorks, Nkarta Therapeutics, Fortress Biotech.
The natural killer cell therapies market is expected to grow at a compound annual growth rate of 16.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Natural Killer Cell Therapies Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Natural Killer Cell Therapies Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Natural Killer Cell Therapies Market - Supply Chain
4.5. Global Natural Killer Cell Therapies Market Forecast
4.5.1. Natural Killer Cell Therapies Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Natural Killer Cell Therapies Market Size (000 Units) and Y-o-Y Growth
4.5.3. Natural Killer Cell Therapies Market Absolute $ Opportunity
5. Global Natural Killer Cell Therapies Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Natural Killer Cell Therapies Market Size and Volume Forecast by Type
5.3.1. NK Cell Therapies
5.3.2. NK Cell Directed Antibodies
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Natural Killer Cell Therapies Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Natural Killer Cell Therapies Market Size and Volume Forecast by Application
6.3.1. Cancer
6.3.2. Gastrointestinal Diseases
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Natural Killer Cell Therapies Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Natural Killer Cell Therapies Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Natural Killer Cell Therapies Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Natural Killer Cell Therapies Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Natural Killer Cell Therapies Demand Share Forecast, 2019-2026
9. North America Natural Killer Cell Therapies Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Natural Killer Cell Therapies Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Natural Killer Cell Therapies Market Size and Volume Forecast by Application
9.4.1. Cancer
9.4.2. Gastrointestinal Diseases
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Natural Killer Cell Therapies Market Size and Volume Forecast by Type
9.7.1. NK Cell Therapies
9.7.2. NK Cell Directed Antibodies
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Natural Killer Cell Therapies Demand Share Forecast, 2019-2026
10. Latin America Natural Killer Cell Therapies Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Natural Killer Cell Therapies Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Natural Killer Cell Therapies Market Size and Volume Forecast by Application
10.4.1. Cancer
10.4.2. Gastrointestinal Diseases
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Natural Killer Cell Therapies Market Size and Volume Forecast by Type
10.7.1. NK Cell Therapies
10.7.2. NK Cell Directed Antibodies
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Natural Killer Cell Therapies Demand Share Forecast, 2019-2026
11. Europe Natural Killer Cell Therapies Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Natural Killer Cell Therapies Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Natural Killer Cell Therapies Market Size and Volume Forecast by Application
11.4.1. Cancer
11.4.2. Gastrointestinal Diseases
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Natural Killer Cell Therapies Market Size and Volume Forecast by Type
11.7.1. NK Cell Therapies
11.7.2. NK Cell Directed Antibodies
11.8. Basis Point Share BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Natural Killer Cell Therapies Demand Share, 2019-2026
12. Asia Pacific Natural Killer Cell Therapies Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Natural Killer Cell Therapies Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Natural Killer Cell Therapies Market Size and Volume Forecast by Application
12.4.1. Cancer
12.4.2. Gastrointestinal Diseases
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Natural Killer Cell Therapies Market Size and Volume Forecast by Type
12.7.1. NK Cell Therapies
12.7.2. NK Cell Directed Antibodies
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Natural Killer Cell Therapies Demand Share, 2019-2026
13. Middle East & Africa Natural Killer Cell Therapies Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Natural Killer Cell Therapies Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Natural Killer Cell Therapies Market Size and Volume Forecast by Application
13.4.1. Cancer
13.4.2. Gastrointestinal Diseases
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Natural Killer Cell Therapies Market Size and Volume Forecast by Type
13.7.1. NK Cell Therapies
13.7.2. NK Cell Directed Antibodies
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Natural Killer Cell Therapies Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Natural Killer Cell Therapies Market: Market Share Analysis
14.2. Natural Killer Cell Therapies Distributors and Customers
14.3. Natural Killer Cell Therapies Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Nektar Therapeutics
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Innate
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Affimed
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Chipscreen Biosciences
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Fate Therapeutics
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Glycostem
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Dragonfly Therapeutics
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Kiadis Pharma
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. NantWorks
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Nkarta Therapeutics
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Fortress Biotech
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
